Evidence map›Paper›PMID 28567125›Full record

ArticleThe open medicinal chemistry journal2017

Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors Bearing a Spirobenzopyran Scaffold.

Maria Digiacomo, Stefania Sartini, Giulia Nesi, Simona Sestito, Vito Coviello, Concettina La Motta, Simona Rapposelli

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The open medicinal chemistry journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maria DigiacomoDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Stefania SartiniDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Giulia NesiDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Simona SestitoDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Vito CovielloDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Concettina La MottaDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Simona RapposelliDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAldose reductase, the first enzyme of the polyol pathway, is the key determinant for the pathogenesis of long term diabetic complications. Accordingly, its inhibition represents the major therapeutic strategy to treat this kind of pathologies.

objectivesIn this work we describe the synthesis and the functional evaluation of a number of spiro-oxazolidinone and spiro-morpholinone acetic acid derivatives, and their benzyloxy analogs, developed as aldose reductase inhibitors.

resultsMost of them proved to inhibit the target enzyme, showing IC

conclusionAlthough further substitution patterns are needed, the novel compounds here proposed represent a good starting point for the development of novel and effective ARIs.

Indexed as

Aldose reductase enzymeAldose reductase inhibitors (ARI)ARL2Diabetic complicationsSpirobenzopyran derivativesSpiromorpholinone derivativesSpiro-oxazolidinones

Identifiers

PMID28567125
PMCPMC5418920
OpenAlexW2588787121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.